Researchers at Weill Cornell Medicine and Roswell Park Comprehensive Cancer Center reported preclinical results showing that intravesical delivery of MUC16-targeting CAR T cells can control bladder tumors in mouse models. The work, co-led by Taha Merghoub, PhD, was published in the Journal of Experimental Medicine. In the study, catheter-based intravesical administration targeted bladder tumor cells directly, aiming to overcome solid-tumor CAR-T barriers such as poor infiltration and off-target toxicity. The team identified MUC16 as a clinically relevant target for anti-bladder-cancer CAR T therapy and reported tumor control in preclinical testing. The authors frame intravesical delivery as a potentially “easy-to-implement” and more effective strategy within established urological practice. If translated, the approach could offer a bladder-sparing option pathway in a disease area with high recurrence and progression rates after standard treatment.